Wednesday, June 19, 2019

The Michigan Alzheimer’s Disease Research Center has announced its third annual Beyond Amyloid Research Symposium taking place on Wednesday, June 19th in Grand Rapids, MI.

8:00 AM to 5:00 PM

MSU Secchia Center,
15 Michigan St NE,
Grand Rapids, MI 49503

An award and networking reception will follow at the MSU Grand Rapids Research Center from 4:30 - 6:30pm (400 Monroe Ave NW, Grand Rapids, MI 49503. This is an 8 minute walk from the Symposium venue).

Keynote speakers include:

Dr. Russel Swerdlow, who will be present “Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease.”


Dr. Linda Van Eldick, who will be present “Targeting Dysregulated Neuroinflammation in Alzheimer’s Disease.”

Dr. Russell Swerdlow

Russel Swerdlow, MD

Director of the University of Kansas Alzheimer’s Disease Center

Russell Swerdlow, M.D., is the Director of the University of Kansas Alzheimer's Disease Center and the KUMC Neurodegenerative Disorders Program. Dr. Swerdlow is a Professor in the Departments of Neurology, Molecular and Integrative Physiology, and Biochemistry and Molecular Biology at the University of Kansas School of Medicine. After receiving his undergraduate and doctor of medicine degrees from New York University, he trained as a neurologist and cognitive disorders subspecialist at the University of Virginia.
Dr. Swerdlow sees patients at the University of Kansas Memory Disorders Clinic. In addition to his clinical side, Dr. Swerdlow is a laboratory-based neuroscientist who is internationally known for his work on mitochondrial dysfunction in neurodegenerative diseases. National level recognition includes the S. Weir Mitchell Award from the American Academy of Neurology, a Cotzias Fellowship from the American Parkinson's Disease Association, research grants from the National Institutes of Health, and membership on NIH and Veteran's Administration Study Sections. Before joining KUMC in 2007, Dr. Swerdlow chaired the Alzheimer's Disease and Related Disorders Commission of the Commonwealth of Virginia, and from 2005-2010 he served as the Research Committee Chair for the CurePSP Foundation.
Dr. Swerdlow's laboratory is currently studying the interaction between genes and cell energy metabolism, the molecular consequences of altered cell energy metabolism, and strategies for repairing defective energy metabolism.
For more information, visit Dr. Swerdlow's University of Kansas Health System bio.

Dr. Linda J. Van Eldik

Linda J. Van Eldik, Ph.D.

Director of University of Kentucky Alzheimer’s Disease Center

Linda J. Van Eldik, Ph.D. is currently director of the Sanders-Brown Center on Aging, at the University of Kentucky.
Previously, as a professor in the Department of Cell and Molecular Biology at Northwestern University Feinberg School of Medicine and associate director of its Cognitive Neurology and Alzheimer’s Disease Center, Van Eldik was recognized for her pioneering work in the area of glia cell biology and the involvement of glia in the pathology of human disease.
Van Eldik’s research has been supported by diverse funding mechanisms, including an NIH Merit Award. She has also served as principal investigator of an NIA training grant on “Drug Discovery Training in Age-related Disorders.” And has received the prestigious Zenith Award from the Alzheimer’s Association, one of only four such awards made in 2009.
Van Eldik received her Ph.D. in microbiology and immunology from Duke University. She was a postdoctoral fellow in virology and cell biology at Rockefeller University before joining the faculty at Vanderbilt University School of Medicine, where she rose to the rank of professor of pharmacology and cell biology.
In addition to her extensive academic service and administrative experiences, Van Eldik also has significant service at the national level, including being a former member of the Medical and Scientific Advisory Council of the Alzheimer's Association, a member of the Scientific Review Board of the Alzheimer’s Drug Discovery Foundation and the International Rett Syndrome Foundation, and service on various government review panels in the area of drug discovery for neurodegenerative diseases.

To be considered for poster presentation:

Please submit an abstract of any topic pertaining to Alzheimer’s disease and related dementias, 250 words or less, by June 3rd, to Erin Fox @ [email protected].
Additional inquiries: [email protected] or 734-232-2459.